Dr. Michel Bazinet, Chief Executive Officer and Chief Medical Officer, Replicor, Inc., joining the Summit from Montreal, Quebec. Dr. Bazinet previously joined Cavendish at the very first Forum in 2014, hosted at the United Nations in New York.

Dr. Bazinet will describe the current prevalence of chronic hepatitis B and the serious medical and social consequences of this disease. He will then review the poor efficacy of currently approved drugs and explain how Replicor is developing a new approach that will revolutionize the management of chronic hepatitis B by offering a new treatment that will generate much higher cure rates with a high safety track record. We will also describe how our drug will also have a major impact in the treatment of chronic hepatitis D which affects between 15 and 30 million people worldwide. Current state of development will be described as well as how new funds will be used to progress toward our ultimate goal of saving millions of lives.

Dr. Michel Bazinet has been the CEO and Chief Medical Officer of Replicor Inc. since 2003. He is responsible for the development strategy of the Company and oversees all operations, including the planning of clinical trials. Previously, Dr. Bazinet worked as assistant professor in the departments of Urology and Oncology at McGill University in Montreal. He did his medical training at Sherbrooke University, his urology training at McGill University after which he did a 3-year fellowship in human tumor immunology and urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York from 1984 to 1987. In 1996 Dr. Bazinet founded a company called Mediconsult and was its Medical Director. Mediconsult became listed on NASDAQ in 1999 and was acquired in 2000. Dr. Bazinet has previously served as a member of the board of Directors for 2 public companies and has been a consultant for many biotechnology projects. Dr. Bazinet is one of the two listed inventors on 239 patents owned by Replicor, of which 169 have already been granted and an additional 70 patents are still pending.

Meet Dr. Bazinet and learn more about Replicor by logging in to Cavendish IQ.

Henry “Chip” R. Appelbaum, President and CEO, Novian Health, joining the Summit from Chicago, IL.

Novian Health is ready for the commercial launch of its proprietary image-guided laser system for focal destruction of tumors.  Novian’s first product, Novilase Breast Therapy, intended as a minimally invasive alternative to lumpectomy, has an addressable market in Europe and the U.S. of $2 billion. It is performed in an outpatient setting such as a breast center.  Novilase has shown improved efficacy at a lower cost versus lumpectomy.  Patients benefit from a quicker recovery (hours not days), no need for cosmetic reconstruction, and improved health-related quality of life outcomes.   An immunotherapeutic benefit may also accrue to patients as a result of the thermal ablation, potentially reducing the risk of recurrence even further.

Recognized as the industry leader in its space, it is the only ablation device with a CE Mark for the treatment of cancerous and benign breast tumors. In the U.S., FDA has de-risked the Company’s path to market with IDE approval for a 510(k) pivotal study that can be completed in less than two years.

Mr. Appelbaum was appointed President and CEO of Novian Health in February of 2005 and has more than 30 years of business development, marketing and sales, and science management experience. Previously, Mr. Appelbaum spent five years as Vice President of Corporate Development at Source Precision Medicine, a molecular diagnostics startup he helped found, and nine years at Amgen where he held different executive positions. He holds an MBA from the University of Chicago and a MS in Chemical Engineering from MIT.

Meet Chip and learn more about Novian Health by logging in to Cavendish IQ.

Introducing Michael Slatter, Chief Executive Officer, Anecare, joining the Summit from Salt Lake City, UT.

Anecare has created ANEclear, the only FDA approved, CE Marked commercially available technology that reverses the effects of anesthetics in the brain to quickly return brain function, breathing and consciousness after surgery; delivering a safer, lower cost recovery. This technology was developed by a team of anesthesiology researchers from the University of Utah and has generated sales of 45,000 disposable devices for adult use and revenue of $2.4M

The effects of anesthesia are widely known and have particular concern for children and seniors:

— 50% of children experience delirium after surgery, which can lead to injury, need for restraint, and other drug intervention.

— Delirium is the most common surgical complication in seniors over age 65, with 20-30% of these patients experiencing cognitive dysfunction.

Recently published research confirms how inhaled anesthetics shut down electrical signaling in neurons in the brain that control brain function, consciousness and breathing. ANEclear’s patented process accelerates washout of the unwanted residual anesthetics from the brain at the end of surgery and restores electrical signaling to return brain function; impacting brain health for kids and seniors during their recovery from anesthesia.